A positive Scl-70 antibody test does not always mean you have scleroderma, but it is one of the strongest antibody markers for the disease. The test has a specificity of about 93% for systemic sclerosis, meaning a small but real percentage of positive results occur in people with other conditions or no autoimmune disease at all. Whether your result is meaningful depends on your symptoms, the type of lab test used, and the clinical picture your doctor sees.
What Scl-70 Antibodies Actually Indicate
Scl-70 antibodies (also called anti-topoisomerase I antibodies) target a specific enzyme involved in DNA replication. Their presence signals that your immune system is producing a very particular type of autoantibody, one strongly linked to systemic sclerosis. In the current classification criteria used by rheumatologists, a positive Scl-70 result earns 3 points out of the 9 needed to classify someone as having definite systemic sclerosis. It carries the same diagnostic weight as anti-centromere or anti-RNA polymerase III antibodies, the other two scleroderma-specific markers.
That said, roughly 15 to 20% of people with confirmed systemic sclerosis actually test positive for Scl-70. So most scleroderma patients are Scl-70 negative, and the antibody’s main diagnostic value is when it does show up: it points strongly toward a specific subtype of the disease and carries information about which organs may be at risk.
When Scl-70 Shows Up Without Scleroderma
False positives happen more often than many patients realize. In one study from a scleroderma referral center, researchers found that the commercial lab tests most commonly used in the U.S. produced enough false positives to raise serious concern about how widespread the problem is. Among patients referred with a positive Scl-70 result, some turned out to have entirely different diagnoses: Sjögren’s syndrome, antiphospholipid antibody syndrome, morphea (a localized form of skin hardening that is distinct from systemic sclerosis), and undifferentiated connective tissue disease.
Scl-70 has also been detected in about 11% of patients with lupus and 8% of patients with mixed connective tissue disease in research settings. These numbers are low compared to the 48% positivity rate seen in patients with the diffuse form of scleroderma, but they show the antibody isn’t exclusive to one condition.
The Lab Method Matters More Than You’d Think
One of the biggest factors in whether your positive result is real or a false alarm is how the lab ran the test. Three common methods are used: multiplex flow immunoassay, ELISA, and immunodiffusion. They do not perform equally.
Multiplex flow immunoassay, a newer automated method widely available through commercial labs, has the poorest specificity of the three. ELISA performs better but still produces a meaningful number of false positives. Immunodiffusion, the oldest technique, is the most reliable. In one study, 95.2% of patients who tested positive on all three methods were clinically confirmed to have systemic sclerosis. When only the less specific methods were positive and immunodiffusion was negative, the likelihood of a true scleroderma diagnosis dropped considerably.
If your result came from a standard commercial lab panel (which typically uses ELISA or multiplex), your doctor may want to confirm the finding with immunodiffusion or evaluate whether your symptoms actually fit the disease before drawing conclusions.
Scl-70 and Disease Severity
When Scl-70 is truly positive in the context of scleroderma, it tells your doctor something important about prognosis. The antibody is found in about 40% of patients with diffuse cutaneous systemic sclerosis, the more widespread form that involves skin thickening across the trunk and limbs. It appears in fewer than 10% of patients with limited cutaneous disease, the subtype that tends to affect the fingers, hands, and face.
Scl-70 positivity is also one of the major risk factors for developing interstitial lung disease, a condition where scar tissue builds up in the lungs and gradually reduces their ability to exchange oxygen. Male sex and having the diffuse skin subtype are the other two major risk factors. This means that if you are Scl-70 positive and do have scleroderma, your doctor will likely monitor your lung function closely with breathing tests and imaging, especially in the first several years after diagnosis.
Scl-70 antibodies are considered mutually exclusive with anti-centromere antibodies, the marker most associated with the limited form of scleroderma. Having both at once is extremely rare, and the presence of one generally rules out the pattern associated with the other.
What a Positive Result Means for You
If you tested positive for Scl-70 but have no symptoms of scleroderma, such as skin tightening, Raynaud’s phenomenon (fingers turning white or blue in the cold), difficulty swallowing, or shortness of breath, a false positive is a real possibility. The test alone does not make a diagnosis. Scleroderma is classified based on a combination of clinical findings, not a single lab value.
Your next steps typically involve a rheumatologist reviewing your full clinical picture: physical exam, other antibody results, nail fold capillary examination (a painless look at the tiny blood vessels near your fingernails), and possibly lung function testing. If the clinical picture doesn’t fit, your doctor may repeat the Scl-70 test using a different, more specific method to check whether the original result was accurate.
For people who are Scl-70 positive with early or subtle symptoms, the result can actually be valuable for catching the disease before it progresses. Early identification of lung involvement or skin changes allows for earlier treatment, which generally leads to better outcomes. The antibody’s real clinical power isn’t as a standalone yes-or-no test. It’s as one piece of a larger diagnostic puzzle that, when genuinely positive, points toward a specific disease pattern and the complications worth watching for.